Cambridge, Mass. — May 6, 2026 — Leads & Copy — Lucent Diagnostics, a brand of Quanterix Corporation, has announced a collaboration with Tempus AI Inc. to broaden access to a novel blood-based biomarker panel designed to improve the accuracy of detecting Alzheimer’s disease.
The agreement will see Tempus AI build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, making the LucentAD® Complete multi-biomarker blood test available for neurologists to order on the Tempus clinical ordering platform.
More than 7 million Americans are living with Alzheimer’s disease, but only a small number are evaluated for eligibility for approved treatments. The collaboration aims to address this gap by embedding clinical guideline-directed identification and blood-based biomarker testing options directly into clinical decision-making workflows used by neurologists.
According to Everett Cunningham, CEO of Quanterix, this collaboration is an important step toward ensuring blood-based Alzheimer’s biomarker testing becomes part of routine clinical practice. He stated that this will be achieved without placing additional burden on providers.
Cunningham added that by working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, the companies are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies. He also stated that collaborations that streamline the diagnostic journey are essential to support earlier, more confident clinical decisions, as they look to advance precision health through high-sensitivity biomarker innovation.
Tempus Next is an AI-enabled care pathway intelligence platform that identifies care gaps and equips providers with actionable insights consistent with clinical guidelines at the point of care. The Tempus Next Care Gap Program helps identify patients who may benefit from biomarker testing based on established clinical guidelines, and clinicians have the option to order LucentAD Complete through existing EHR integrations.
Lucent Diagnostics, a commercial brand of Quanterix, was created in 2023 to deliver tools that aid in the earlier detection of cognitive disease. Powered by the Simoa® technology, Lucent Diagnostics aims to bridge the gap between research and clinical use by offering products and services designed specifically to meet the separate needs of institutions and healthcare providers.
With more than a decade of experience in the neurology research space, supported by thousands of publications and partnerships, Quanterix aims to directly impact the landscape of cognitive disease through its commercial brand, Lucent Diagnostics.
Source: Lucent Diagnostics
